1. <th id="ya0vw"><sup id="ya0vw"></sup></th>
      <pre id="ya0vw"><small id="ya0vw"><input id="ya0vw"></input></small></pre>
    2. <pre id="ya0vw"><small id="ya0vw"><p id="ya0vw"></p></small></pre>
      <strike id="ya0vw"></strike>
    3. <code id="ya0vw"></code>

      www.247cinema.cn 提示:

      本信息僅供醫學專業人士參考,如果您是醫學專業人士,請點擊確定后進入。 如果不是,請點擊取消。

      取消 確定

      Products and services

      In 3SBio, meeting the needs of patients is the core of all actions.

      Our global list of drug combinations

      The following is a list of products listed by our company, which is only for medical professionals to refer to.

      YISAIPU (Recombinant human type II tumor necrosis factor receptor - antibody fusion protein)

      YISAIPU was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of China. 3 kinds of indications were approved by the NMPA: Treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). It is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

      Indication Manufacturing base Dosage form & Dosage
      Moderate to severe rheumatoid arthritis;
      Moderate to severe plaque psoriasis (PS) in adults aged 18 or above;
      Active ankylosing spondylitis.
      Shanghai manufacturing base 12.5 mg/bottle; 25 mg/bottle